@article{ref1,
title="Sitagliptin induced splenic infarcts",
journal="Clinical Diabetology",
year="2017",
author="Misgar, R.A. and Bhat, J.A. and Wani, A.I. and Bashir, M.I.",
volume="6",
number="6",
pages="215-217",
abstract="Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remarkably well tolerated oral antihyperglycemic drugs with an adverse effect profile similar to that of placebo. No adverse effects have been reported even with overdose of sitagliptin in suicide attempts. We present here case summary of a 35-year-old female with type 2 diabetes mellitus and major depressive disorder who presented with multiple splenic infarcts after ingestion of sitagliptin 700 mg and metformin 14 g with suicidal intent. To the best of our knowledge, there are no published reports of splenic infarcts as an adverse event of sitagliptin.<p /><p>Language: en</p>",
language="en",
issn="2450-7458",
doi="10.5603/DK.2017.0035",
url="http://dx.doi.org/10.5603/DK.2017.0035"
}